We recently published 10 Stocks With Massive Gains; 5 at Record Highs. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) was one ...
Explore the impact of drug discovery automation in 2026, addressing complexity and improving decision-making across ...
Eli Lilly is a well-established pharmaceutical company with a portfolio of products that consistently generate revenue and ...
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) ranks among the best AI stocks to buy according to analysts. On December 17, ...
Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its CEO & President, Najat Khan, Ph.D., will present Tuesday, January 13 ...
Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) is one of the AI stocks under $20 to buy now. On December 8, Recursion ...
Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
On December 17, 2025, JPMorgan raised Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) from Neutral to Overweight, with a price ...
How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Recursion plans to present updated data from the TUPELO trial in an upcoming webinar scheduled for December 8, 2025. This presentation will provide further insights into the drug’s safety and efficacy ...
Zacks Investment Research on MSN
Recursion Pharmaceuticals (RXRX) stock sinks as market gains: What you should know
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $4.70, marking a -3.29% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.01%.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback